Innovative Gene Therapy Access Model for Sickle Cell Disease Could Benefit the IRD Community

For individuals and families navigating Inherited Retinal Diseases (IRDs), the promise of gene therapy offers a beacon of hope for preserving or restoring vision. However, the high cost and complex access pathways for these cutting-edge treatments remain significant hurdles. A recent development in the sickle cell disease (SCD) community, detailed in a Forbes article, highlights a novel access model for gene therapies that could potentially serve as a template for other rare genetic conditions, including IRDs. This initiative aims to make life-changing gene therapies more accessible and affordable, a goal deeply resonant with the IRD community.

A New Approach to Gene Therapy Access

The Centers for Medicare and Medicaid Services (CMS) launched a Cell and Gene Therapy (CGT) Access Model in January 2024, initially focusing on gene therapies for sickle cell disease. This voluntary program, which began state participation between January 2025 and January 2026, involves 33 states, the District of Columbia, and Puerto Rico. These participating regions represent approximately 84% of Medicaid beneficiaries with SCD. The model aims to improve patient access and lower costs for gene therapies targeting sickle cell disease.

Under this model, the federal government negotiates outcomes-based agreements with manufacturers on behalf of state Medicaid agencies. This means that payment for the two novel gene therapies for SCD, Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel), which have launch prices of $2.2 million and $3.1 million respectively, is tied to positive clinical outcomes. If a therapy fails to deliver its promised clinical benefits, states receive guaranteed discounts or rebates. This approach aims to expand access to curative treatments while protecting state budgets.

What This Means for Patients and Families

The high upfront costs of gene therapies have been a major barrier to access for many patients with rare diseases. By linking payment to patient outcomes, this new model could make these potentially transformative treatments more widely accessible. Medicaid is the primary insurer for many SCD patients, and this program could significantly expand access to care for a large population. The model also covers comprehensive support, including consultations, evaluations, care coordination, disease management, fertility preservation services, and post-treatment follow-up care.

For the IRD community, this innovative framework offers a glimpse into how similar challenges might be overcome. As more gene therapies for IRDs emerge, a successful model like this could provide a blueprint for ensuring that these treatments reach those who need them, regardless of their financial situation. The CMS has indicated that if this model proves successful, it could expand to include other diseases with high-cost, high-impact therapies in the future.

Looking Ahead

The success of the Cell and Gene Therapy Access Model for sickle cell disease will be closely watched by the broader rare disease community. If effective in improving access and managing costs, this model could indeed serve as a template for future cell and gene therapy agreements, potentially opening doors for individuals with inherited retinal diseases to access life-changing treatments.